18f-NAF PET /BT'nin metastatik kemik hastalığının gösterilmesindeki rolü
MetadataShow full item record
OBJECTIVE: To investigate the role of 18F-NaF PET/CT in detecting metastatic bone disease and to compare with Tc-99m MDP whole body bone scintigraphyand 18F-FDG PET/CT.MATERIAL AND METHOD: Histopathologically proven 37 cancer patients (mean age 58.19) with known bone metastasis were included in the study. All patients had bone scintigraphy and 18F-NaF PET/CT. The results of 18F-FDG PET/CT in 12 (%32) patients and In-111 octreotide scintigraphy in 2 (%0.5)patients were included in evaluation.RESULTS: Bone scan and 18F-NaF PET/CT were positive for metastasi in all patients. However, the number of lesions demonstrated was equal in 4/37 (%10)of the cases. 18F-NaF PET/CT showed a greater number of pathological foci inthe others. Because 18F-NaF PET/CT could show both lytic, blastic and small lesions, due to the advantage of sectional imaging and much better resolution and high target/background ratio. The comparison results of 18F-FDG PET/CT and 18F-NaF PET/CT revealed that 18F-NaF PET/CT demonstrated a greaternumber of metastases in 10/12 (83%) of the patients. They showed the same lesions in the rest of the cases. 18F-NaF PET/CT could show both blastic and sclerotic lesions. The uptake of 18F-FDG was variable in blastic lesions.Additionally, the cranial bone involvement that 18F-FDG PET/CT missed because physiological brain metabolism masked could be easily differentiated by 18F-NaF PET/CT. While bone marrow involvement could not be demonstrated in the bone scans, 18F-NaF revealed in 5 (13%) patients. The CT component of 18F-NaF PET/CT was primarily helpful in differentiating degenerative lesions from metastasis by better localisation of metastatic foci on the extremities close to the joints.CONCLUSION: 18F-NaF PET/CT is a more effective modality in bonemetastasis when compared with bone scan and 18F-FDG PET/CT and can be performed as the first scanning method for evaluation of bone metastasis.